Exelixis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.
CEOMichael M. Morrissey
CEOMichael M. Morrissey
Employees1,147
Employees1,147
HeadquartersAlameda, California
HeadquartersAlameda, California
Founded1994
Founded1994
Employees1,147
Employees1,147
EXEL Key Statistics
Market cap10.89B
Market cap10.89B
Price-Earnings ratio19.40
Price-Earnings ratio19.40
Dividend yield—
Dividend yield—
Average volume2.29M
Average volume2.29M
High today$40.78
High today$40.78
Low today$38.90
Low today$38.90
Open price$39.66
Open price$39.66
Volume2.66M
Volume2.66M
52 Week high$49.62
52 Week high$49.62
52 Week low$25.17
52 Week low$25.17
EXEL News
TipRanks 19h
Exelixis: Strong Growth Potential with Promising Zanzalintinib Outlook and Attractive Investment OpportunityPaul Choi, an analyst from Goldman Sachs, has initiated a new Buy rating on Exelixis (EXEL). Elevate Your Investing Strategy: Take advantage of TipRanks Premium...
TipRanks 21h
Exelixis price target raised to $50 from $46 at Morgan StanleyMorgan Stanley raised the firm’s price target on Exelixis (EXEL) to $50 from $46 and keeps an Overweight rating on the shares. Zanzalintinib represents an area...
TipRanks 2d
Adagene expands SAFEbody collaboration, license agreement with ExelixisAdagene (ADAG) announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will uti...
Analyst ratings
57%
of 21 ratingsBuy
57.1%
Hold
42.9%
Sell
0%
People also own
Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.